TwinBeech Capital’s BridgeBio Pharma BBIO Stock Holding History

TwinBeech Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$737K	Buy	+9,900	New	+$693K	0.13%	182
2025 Q2	–	Sell	-321,811	Closed	-$11.1M	–	649
2025 Q1	$11.1M	Buy	+321,811	New	+$10.9M	0.2%	135
2024 Q4	–	Sell	-77,798	Closed	-$1.98M	–	622
2024 Q3	$1.98M	Sell	77,798 -263,449	-77%	-$6.92M	0.04%	409
2024 Q2	$8.64M	Buy	+341,247	New	+$9.33M	0.17%	153
2023 Q4	–	Sell	-107,409	Closed	-$2.83M	–	654
2023 Q3	$2.83M	Buy	+107,409	New	+$3.05M	0.05%	355
2023 Q1	–	Sell	-264,325	Closed	-$2.01M	–	618
2022 Q4	$2.01M	Buy	+264,325	New	+$2.53M	0.04%	439
2022 Q1	–	Sell	-54,398	Closed	-$907K	–	501
2021 Q4	$907K	Buy	54,398 +45,442	+507%	+$1.92M	0.05%	359
2021 Q3	$420K	Buy	+8,956	New	+$480K	0.03%	453

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

TwinBeech Capital's BBIO Position: Q2 2026 in Review

TwinBeech Capital opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 9,900 shares worth $737K. The stake represents 0.13% of the portfolio and ranks #182 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in BBIO as recently as Q1 2025.

TwinBeech Capital first reported a position in BBIO in Q3 2021 and has held it in 8 quarters since. The position peaked at $11.1M in Q1 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

TwinBeech Capital held 9,900 shares of BridgeBio Pharma worth $737K as of Q2 2026.
BridgeBio Pharma was a new TwinBeech Capital position in Q2 2026.
BridgeBio Pharma made up 0.13% of TwinBeech Capital's portfolio in Q2 2026, its #182 holding.
TwinBeech Capital first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 8 quarters since.
TwinBeech Capital's BridgeBio Pharma position peaked at $11.1M in Q1 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.